Issue 11, 2020

Pregnenolonyl-α-glucoside exhibits marked anti-cancer and CYP17A1 enzymatic inhibitory activities

Abstract

We report here that pregnenolonyl-α-glucoside (2), a steryl glycoside synthesized directly from pregnenolone and glucose via a consecutive multienzyme-catalyzed process, exhibits marked dose-dependent cytotoxic activity against HT29, AGS, and ES-2 cells with IC50 values of 23.5 to 50.9 μM. An in vitro CYP17A1 binding pattern assay and protein–ligand docking model support that 2, like abiraterone, binds in the active site heme iron pocket of CYP17A1.

Graphical abstract: Pregnenolonyl-α-glucoside exhibits marked anti-cancer and CYP17A1 enzymatic inhibitory activities

Supplementary files

Article information

Article type
Communication
Submitted
04 Dec 2019
Accepted
08 Jan 2020
First published
08 Jan 2020

Chem. Commun., 2020,56, 1733-1736

Pregnenolonyl-α-glucoside exhibits marked anti-cancer and CYP17A1 enzymatic inhibitory activities

F. Chou, W. Hsu, S. Huang, C. Chang, Y. Chiou, C. Tsai, J. W. Lyu, W. Chen and T. Wu, Chem. Commun., 2020, 56, 1733 DOI: 10.1039/C9CC09415F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements